by immunization, and has been an advocate of improved immunization of adults. He has served on the Advisory Committee on Immunization Practices and the National Vaccine Advisory Committee, and was the first chair of FDA’s Vaccines and Related Biological Products Advisory Committee. In addition, he has served as president of both the Infectious Disease Society of America and the American Epidemiological Society.
Patricia Ferrieri, M.D., is Professor of Laboratory Medicine and Pathology and Pediatrics at the University of Minnesota Medical School, Minneapolis, Minnesota, and Director of the Clinical Microbiology Laboratory at Fairview-University Medical Center, Minneapolis. She is also a member of the Pediatric Infectious Diseases Division. Her research interests include protein antigens of group B streptococci (GBS), pathogenesis of infection, host immunity, and animal models of bacterial infection and protection. In addition, she is involved in molecular characterization/epidemiology of GBS and other bacteria, neonatal infections, and bacterial vaccines. She is a former chairperson of the NIH Bacteriology and Mycology Study Section and the former chair of the FDA Vaccines and Related Biological Products Advisory Committee, and is knowledgeable in regulatory and licensing procedures.
Emil C. Gotschlich, M.D., is vice president for medical sciences at The Rockefeller University, where he is also R. Gwin Follis-Chevron Professor and head of the Laboratory of Bacterial Pathogenesis and Immunology. His early work led to the development of a vaccine for the prevention of group A and C meningococcal meningitis. His research has also been directed at the surface structures responsible for the pathogenicity of group B streptococci and gonococcus. Dr. Gotschlich is a fellow of the American Academy of Microbiology and is a member of both the National Academy of Sciences and the Institute of Medicine.
Maurice Hilleman, Ph.D., D.Sc., has been engaged for nearly six decades in basic and applied research in academia, government, and industry. He was formerly director and senior vice president, Merck Institute of Therapeutic Research. He is presently director of the recently formed Merck Institute for Vaccinology. As a virologist-infectious disease scientist, Dr. Hilleman has been engaged in broad-spectrum programs in basic research discovery in virology and viral immunology and in targeted research, which has yielded a large number of vaccines, including measles, mumps, rubella, varicella and combined MMR, pneumococcus, meningococcus, H. influenzae, hepatitis A, and hepatitis B that are now used routinely. His most recent work has focused on vaccine development, improvement, and application, with emphasis on public health policy and worldwide utilization. He engages in summary simplification of the molecular biology, pathogenesis, epidemiology, and immune prophylaxis of a number of viral infections. Other interests include AIDS, hepatitis, virus in cancer, immunology, vaccinology, public policy, and world health applications. Dr. Hilleman serves on the Committee to Review Research Proposals from Former Soviet Biological Weapons Institutes for the National Research Council Office of International Affairs and the U.S. Civilian Research and Development Foundation (CRDF), and is an elected member of both the National Academy of Sciences and the Institute of Medicine.
Dennis L. Kasper, M.D., is executive dean for academic programs, William Ellery Channing Professor of Medicine, and professor of microbiology and molecular genetics at Harvard Medical School. He also serves as director of the Channing Laboratory and as a senior physician at Brigham and Women’s Hospital. With his colleagues and students, Dr. Kasper studies the molecular basis of bacterial pathogenesis, applying the resulting knowledge to enhance understanding of the interactions of bacterial surface virulence factors with host defenses. Dr. Kasper’s studies focus on the molecular and chemical characterization of important bacterial virulence factors such as capsular polysaccharides, surface proteins, and toxins. The ultimate goal is to develop vaccines and immunomodulatory molecules to prevent bacterial infections